| pubmed-article:8402936 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C0017349 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C1548437 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C1322978 | lld:lifeskim |
| pubmed-article:8402936 | lifeskim:mentions | umls-concept:C0599796 | lld:lifeskim |
| pubmed-article:8402936 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8402936 | pubmed:dateCreated | 1993-11-5 | lld:pubmed |
| pubmed-article:8402936 | pubmed:abstractText | Treatment of skin with the chemical carcinogen 7,12-dimethylbenz[a]anthracene (DMBA), which reduces the density of epidermal class II MHC-expressing Langerhans cells (LC), enhances its survival when transplanted onto histoincompatible hosts. We have examined the ability of T lymphocytes which reject DMBA-treated skin to lyse P388D1 cells expressing either only class I or class I and II antigens. Lymphocytes isolated from solvent-treated grafts showed greater cytotoxicity for the targets expressing both antigens, indicating that some of these lymphocytes were specific for class II MHC antigens. In contrast, lymphocytes isolated from carcinogen-treated grafts lysed both targets similarly and hence did not contain any cells specific for class II MHC antigens. Anti-class I MHC antibody blocked cytotoxicity by both leukocyte populations to similar extents, but anti-class II MHC antibodies preferentially blocked T cells isolated from the solvent-treated grafts. There was no difference in the phenotype of the cytotoxic cells isolated from solvent- and carcinogen-treated grafts. Thus, whereas solvent-treated skin grafts are rejected by T cells specific for class I and II MHC antigens, DMBA-treated skin grafts are only rejected by class I MHC-specific T cells which may account for the enhanced survival of the carcinogen-treated grafts. | lld:pubmed |
| pubmed-article:8402936 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8402936 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402936 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8402936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402936 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8402936 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8402936 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:8402936 | pubmed:author | pubmed-author:MullerH KHK | lld:pubmed |
| pubmed-article:8402936 | pubmed:author | pubmed-author:HallidayG MGM | lld:pubmed |
| pubmed-article:8402936 | pubmed:author | pubmed-author:OdlingK AKA | lld:pubmed |
| pubmed-article:8402936 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8402936 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8402936 | pubmed:volume | 151 | lld:pubmed |
| pubmed-article:8402936 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8402936 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8402936 | pubmed:pagination | 291-9 | lld:pubmed |
| pubmed-article:8402936 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:meshHeading | pubmed-meshheading:8402936-... | lld:pubmed |
| pubmed-article:8402936 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8402936 | pubmed:articleTitle | Carcinogen-treated skin allografts rejected by T lymphocytes specific for class I but not class II MHC antigens. | lld:pubmed |
| pubmed-article:8402936 | pubmed:affiliation | Department of Dermatology, University of Sydney, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. | lld:pubmed |
| pubmed-article:8402936 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8402936 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
